06.25.25 -- Early-Phase Formulation Done Right: An Expert Analysis

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

Explore how CMOs are playing a pivotal role in enabling pharmaceutical companies to optimize their operations and how this collaboration is reshaping the future of pharmaceutical manufacturing.

Developing a safe and effective injectable combination product involves performing risk assessments, establishing a set of Critical Quality Attributes (CQAs), and performing design verification testing.

In biologics and cell and gene therapy (CGT), selecting and managing a CDMO has become a strategic imperative. Unfortunately, traditional approaches to external partners can fall short. But now AI is reshaping this landscape. Analysis from an Outsourced Pharma Board member.

We showcase the development of high drug load nanocrystal based tablets and prove that nanocrystals can match the pharmacokinetic performance of ASDs while reducing the overall pill burden.

Examine how a platform integrating drug substance, drug product, and clinical testing within a single organization accelerates development and reduces costs, helping deliver positive outcomes earlier.

When facing a malfunction, having an effective disaster recovery plan can make the difference between a swift fix, and losing your samples and time.

Our network can support discovery, clinical, and commercial programs for NCEs, with a business model that does not add costs to your project. Review our network's regulatory starting material capabilities.

Learn how defined workflows to assess and select solid forms in a cost and time-efficient manner can meet the needs of each program.